Contact Us   |   Print Page   |   Sign In   |   Join
News and Press: Member Organization News

Gemphire's Lead Drug Shows Promising Results

Wednesday, September 21, 2016   (0 Comments)
Posted by: Kate Oesterle
Share |

Promising results for gemcabene, the lead drug for Livonia-based Gemphire Therapeutics Inc., have been published in the Journal of Clinical Lipidology.

The results were from Phase 2 trials of human patients with high cholesterol who were already being treated with the statin class of drugs and statistically significant reductions in lower density lipoprotein, the so-called bad cholesterol, and other markers for heart disease.

Patients were given either a placebo, 300 milligrams of gemcabene or 900 milligrams. The drug was taken orally once a day.

Patients getting 300 milligrams saw a reduction in LDL of 23.4 percent and those getting 900 milligrams saw reductions of 27.7 percent, compared to 6.2 percent for the placebo.

Read full article.

Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by YourMembership  ::  Legal